NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
Novartis AG raised its medium-term sales guidance, citing upbeat expectations for new cancer and immunological disease medicines, as well as treatments for neurological and cardiovascular conditions.
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
Novartis signs deal with Mass. company worth up to $745M
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
/PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for...
Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
July 2025 Options Now Available For Novartis (NVS)
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
Novartis (NVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks.com featured highlights include Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital
Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital have been highlighted in this Screen of The Week article.
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
Novartis (NVS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Novartis (NVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart.
Is NYSE:NVS suited for dividend investing?
Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).
Oversold Conditions For Novartis (NVS)
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2024.
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Novartis Reports Q3 Momentum, But Shares Lose Support
Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook.
Novartis Boosts Profit Forecast as Sales of New Drugs Rise
Novartis AG boosted its annual profit guidance for the third straight quarter, helped by rising sales of its blockbuster medicines for psoriasis and cancer.
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.